{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:54:07Z","timestamp":1789430047531,"version":"build-2803163510"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-025-03807-9","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T08:26:50Z","timestamp":1761208010000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bevacizumab and beyond: investigating the role of combination therapies in the management of retinal diseases"],"prefix":"10.1007","volume":"45","author":[{"given":"Masoumeh Sadat","family":"Hor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soheila","family":"Rahgozar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Souri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Malekahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"issue":"10397","key":"3807_CR1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","volume":"402","author":"KL Ong","year":"2023","unstructured":"Ong KL, Stafford LK, McLaughlin SA, Boyko EJ, Vollset SE, Smith AE et al (2023) Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the global burden of disease study 2021. Lancet 402(10397):203\u2013234. https:\/\/doi.org\/10.1016\/S0140-6736(23)01301-6","journal-title":"Lancet"},{"key":"3807_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12886-018-0710-9","volume":"18","author":"R Thapa","year":"2018","unstructured":"Thapa R, Bajimaya S, Paudyal G, Khanal S, Tan S, Thapa SS et al (2018) Prevalence and causes of low vision and blindness in an elderly population in Nepal: the Bhaktapur retina study. BMC Ophthalmol 18:1\u201310. https:\/\/doi.org\/10.1186\/s12886-018-0710-9","journal-title":"BMC Ophthalmol"},{"key":"3807_CR3","doi-asserted-by":"publisher","first-page":"1149708","DOI":"10.3389\/fphar.2023.1149708","volume":"14","author":"Q He","year":"2023","unstructured":"He Q, Xiao L, Shi Y, Li W, Xin X (2023) Natural products: protective effects against ischemia-induced retinal injury. Front Pharmacol 14:1149708. https:\/\/doi.org\/10.3389\/fphar.2023.1149708","journal-title":"Front Pharmacol"},{"issue":"7","key":"3807_CR4","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1016\/j.biocel.2013.04.013","volume":"45","author":"A Klettner","year":"2013","unstructured":"Klettner A, Kauppinen A, Blasiak J, Roider J, Salminen A, Kaarniranta K (2013) Cellular and molecular mechanisms of age-related macular degeneration: from impaired autophagy to neovascularization. Int J Biochem Cell Biol 45(7):1457\u20131467. https:\/\/doi.org\/10.1016\/j.biocel.2013.04.013","journal-title":"Int J Biochem Cell Biol"},{"issue":"4","key":"3807_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19040942","volume":"19","author":"A R\u00fcbsam","year":"2018","unstructured":"R\u00fcbsam A, Parikh S, Fort PE (2018) Role of inflammation in diabetic retinopathy. Int J Mol Sci 19(4):942. https:\/\/doi.org\/10.3390\/ijms19040942","journal-title":"Int J Mol Sci"},{"issue":"6","key":"3807_CR6","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.ophtha.2010.01.058","volume":"117","author":"SL Rogers","year":"2010","unstructured":"Rogers SL, McIntosh RL, Lim L, Mitchell P, Cheung N, Kowalski JW et al (2010) Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 117(6):1094\u2013101.e5. https:\/\/doi.org\/10.1016\/j.ophtha.2010.01.058","journal-title":"Ophthalmology"},{"issue":"4","key":"3807_CR7","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1097\/IAE.0b013e31815ec29b","volume":"28","author":"SS Hayreh","year":"2008","unstructured":"Hayreh SS, Fraterrigo L, Jonas J (2008) Central retinal vein occlusion associated with cilioretinal artery occlusion. Retina 28(4):581\u2013594. https:\/\/doi.org\/10.1097\/IAE.0b013e31815ec29b","journal-title":"Retina"},{"issue":"9","key":"3807_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0108196","volume":"9","author":"X Chen","year":"2014","unstructured":"Chen X, Rong SS, Xu Q, Tang FY, Liu Y, Gu H et al (2014) Diabetes mellitus and risk of age-related macular degeneration: a systematic review and meta-analysis. PLoS ONE 9(9):e108196. https:\/\/doi.org\/10.1371\/journal.pone.0108196","journal-title":"PLoS ONE"},{"key":"3807_CR9","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.2147\/OPTH.S489114","volume":"18","author":"LS Aldokhail","year":"2024","unstructured":"Aldokhail LS, Alhadlaq AM, Alaradi LM, Alaradi LM, AlShaikh FY (2024) Outcomes of anti-VEGF therapy in eyes with diabetic macular edema, vein occlusion-related macular edema, and neovascular age-related macular degeneration: a systematic review. Clin Ophthalmol 18:3837\u20133851. https:\/\/doi.org\/10.2147\/OPTH.S489114","journal-title":"Clin Ophthalmol"},{"key":"3807_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00417-010-1452-4","volume":"249","author":"S Goyal","year":"2011","unstructured":"Goyal S, LaValley M, Subramanian ML (2011) Meta-analysis and review on the effect of bevacizumab in diabetic macular edema. Clin Exp Ophthalmol 249:15\u201327. https:\/\/doi.org\/10.1007\/s00417-010-1452-4","journal-title":"Clin Exp Ophthalmol"},{"issue":"12","key":"3807_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2019.107417","volume":"33","author":"RP Singh","year":"2019","unstructured":"Singh RP, Elman MJ, Singh SK, Fung AE, Stoilov I (2019) Advances in the treatment of diabetic retinopathy. J Diabet Complicat 33(12):107417. https:\/\/doi.org\/10.1016\/j.jdiacomp.2019.107417","journal-title":"J Diabet Complicat"},{"key":"3807_CR12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/1874364101307010004","volume":"7","author":"N Gupta","year":"2013","unstructured":"Gupta N, Mansoor S, Sharma A, Sapkal A, Sheth J, Falatoonzadeh P et al (2013) Diabetic retinopathy and VEGF. Open Ophthalmol J 7:4\u201310. https:\/\/doi.org\/10.2174\/1874364101307010004","journal-title":"Open Ophthalmol J"},{"issue":"1","key":"3807_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19010110","volume":"19","author":"C Altmann","year":"2018","unstructured":"Altmann C, Schmidt MH (2018) The role of microglia in diabetic retinopathy: inflammation, microvasculature defects and neurodegeneration. Int J Mol Sci 19(1):110. https:\/\/doi.org\/10.3390\/ijms19010110","journal-title":"Int J Mol Sci"},{"key":"3807_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.910600","volume":"9","author":"Y Tang","year":"2022","unstructured":"Tang Y, Cheng Y, Wang S, Wang Y, Liu P, Wu H (2022) The development of risk factors and cytokines in retinal vein occlusion. Front Med 9:910600. https:\/\/doi.org\/10.3389\/fmed.2022.910600","journal-title":"Front Med"},{"key":"3807_CR15","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/5185128","volume":"2019","author":"H Noma","year":"2019","unstructured":"Noma H, Yasuda K, Shimura M (2019) Cytokines and the pathogenesis of macular edema in branch retinal vein occlusion. J Ophthalmol 2019:5185128. https:\/\/doi.org\/10.1155\/2019\/5185128","journal-title":"J Ophthalmol"},{"issue":"6","key":"3807_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19061816","volume":"19","author":"W Wang","year":"2018","unstructured":"Wang W, Lo AC (2018) Diabetic retinopathy: pathophysiology and treatments. Int J Mol Sci 19(6):1816. https:\/\/doi.org\/10.3390\/ijms19061816","journal-title":"Int J Mol Sci"},{"issue":"5","key":"3807_CR17","doi-asserted-by":"publisher","first-page":"976","DOI":"10.4103\/1673-5374.355743","volume":"18","author":"L Tang","year":"2023","unstructured":"Tang L, Xu GT, Zhang JF (2023) Inflammation in diabetic retinopathy: possible roles in pathogenesis and potential implications for therapy. Neural Regen Res 18(5):976\u2013987. https:\/\/doi.org\/10.4103\/1673-5374.355743","journal-title":"Neural Regen Res"},{"key":"3807_CR18","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ajo.2017.01.010","volume":"176","author":"RN Parikh","year":"2017","unstructured":"Parikh RN, Traband A, Kolomeyer AM, VanderBeek BL, Kim BJ, Maguire AM et al (2017) Intravitreal bevacizumab for the treatment of vitreous hemorrhage due to proliferative diabetic retinopathy. Am J Ophthalmol 176:194\u2013202. https:\/\/doi.org\/10.1016\/j.ajo.2017.01.010","journal-title":"Am J Ophthalmol"},{"key":"3807_CR19","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s00417-010-1303-3","volume":"248","author":"R Di Lauro","year":"2010","unstructured":"Di Lauro R, De Ruggiero P, Di Lauro R, Di Lauro MT, Romano MR (2010) Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Clin Exp Ophthalmol 248:785\u2013791. https:\/\/doi.org\/10.1007\/s00417-010-1303-3","journal-title":"Clin Exp Ophthalmol"},{"issue":"5","key":"3807_CR20","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1586\/era.12.13","volume":"12","author":"MI Braghiroli","year":"2012","unstructured":"Braghiroli MI, Sabbaga J, Hoff PM (2012) Bevacizumab: overview of the literature. Expert Rev Anticancer Ther 12(5):567\u2013580. https:\/\/doi.org\/10.1586\/era.12.13","journal-title":"Expert Rev Anticancer Ther"},{"issue":"11","key":"3807_CR21","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.1038\/s41433-020-01384-y","volume":"35","author":"YJ Park","year":"2021","unstructured":"Park YJ, Ahn J, Kim TW, Park SJ, Joo K, Park KH et al (2021) Efficacy of bevacizumab for vitreous haemorrhage in proliferative diabetic retinopathy with prior complete panretinal photocoagulation. Eye 35(11):3056\u20133063. https:\/\/doi.org\/10.1038\/s41433-020-01384-y","journal-title":"Eye"},{"issue":"10","key":"3807_CR22","doi-asserted-by":"publisher","first-page":"992","DOI":"10.3390\/diagnostics14100992","volume":"14","author":"K Kati\u0107","year":"2024","unstructured":"Kati\u0107 K, Kati\u0107 J, Kumri\u0107 M, Bo\u017ei\u0107 J, Tandara L, \u0160upe Domi\u0107 D, Bu\u0107an K (2024) The predictors of early treatment effectiveness of intravitreal bevacizumab application in patients with diabetic macular edema. Diagnostics 14(10):992. https:\/\/doi.org\/10.3390\/diagnostics14100992","journal-title":"Diagnostics"},{"issue":"5","key":"3807_CR23","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1177\/112067212096205","volume":"31","author":"S Balla","year":"2021","unstructured":"Balla S, Zold E, Potor L, Lukucz B, Vajas A, Ujhelyi B, Nagy V (2021) Analysis of intravitreal bevacizumab treatment for macular oedema due to retinal vein occlusion. Eur J Ophthalmol 31(5):2528\u20132534. https:\/\/doi.org\/10.1177\/112067212096205","journal-title":"Eur J Ophthalmol"},{"issue":"3","key":"3807_CR24","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3928\/23258160-20240108-01","volume":"55","author":"RP Singh","year":"2024","unstructured":"Singh RP, Avery RL, Barakat MR, Kim JE, Kiss S (2024) Evidence-based use of bevacizumab in the management of neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging Retina 55(3):156\u2013162. https:\/\/doi.org\/10.3928\/23258160-20240108-01","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"13","key":"3807_CR25","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/nejmoa1414264","volume":"372","author":"JA Wells","year":"2015","unstructured":"Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN et al (2015) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372(13):1193\u20131203. https:\/\/doi.org\/10.1056\/nejmoa1414264","journal-title":"N Engl J Med"},{"issue":"1","key":"3807_CR26","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1001\/jamaophthalmol.2015.4110","volume":"134","author":"JS Heier","year":"2016","unstructured":"Heier JS, Bressler NM, Avery RL, Bakri SJ, Boyer DS, Brown DM, Dugel PU, Freund KB, Glassman AR, Kim JE (2016) Comparison of aflibercept, bevacizumab, and ranibizumab for treatment of diabetic macular edema: extrapolation of data to clinical practice. JAMA Ophthalmol 134(1):95\u201399. https:\/\/doi.org\/10.1001\/jamaophthalmol.2015.4110","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"3807_CR27","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/j.ophtha.2009.03.016","volume":"116","author":"JF Arevalo","year":"2009","unstructured":"Arevalo JF, Sanchez JG, Wu L, Maia M, Alezzandrini AA, Brito M et al (2009) Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American collaborative retina study group at 24 months. Ophthalmology 116(8):1488\u201397.e1. https:\/\/doi.org\/10.1016\/j.ophtha.2009.03.016","journal-title":"Ophthalmology"},{"issue":"3","key":"3807_CR28","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.ophtha.2020.07.062","volume":"128","author":"MH Maloney","year":"2021","unstructured":"Maloney MH, Payne SR, Herrin J, Sangaralingham LR, Shah ND, Barkmeier AJ (2021) Risk of systemic adverse events after intravitreal bevacizumab, ranibizumab, and aflibercept in routine clinical practice. Ophthalmology 128(3):417\u2013424. https:\/\/doi.org\/10.1016\/j.ophtha.2020.07.062","journal-title":"Ophthalmology"},{"issue":"2","key":"3807_CR29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.51329\/mehdioptometry175","volume":"4","author":"AL Gramajo","year":"2023","unstructured":"Gramajo AL, Aucar ME, Laborie MV, Schlottman PG, Luna JD (2023) Systemic complications of intravitreal bevacizumab: a case report and literature review. Med Hypoth Dis Innovat Optomet 4(2):63\u201375","journal-title":"Med Hypoth Dis Innovat Optomet"},{"issue":"6","key":"3807_CR30","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s00417-017-3624-y","volume":"255","author":"B Bahrami","year":"2017","unstructured":"Bahrami B, Hong T, Zhu M, Schlub TE, Chang A (2017) Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 255(6):1133\u20131140","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"3807_CR31","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/ICB.0b013e3181578dd8","volume":"3","author":"ME Torres-Soriano","year":"2009","unstructured":"Torres-Soriano ME, Reyna-Castel\u00e1n E, Hern\u00e1ndez-Rojas M, Garc\u00eda-Aguirre G, Kon-Jara V, Diaz-Rubio JL et al (2009) Tractional retinal detachment after intravitreal injection of bevacizumab in proliferative diabetic retinopathy. Retin Cases Brief Rep 3(1):70\u201373. https:\/\/doi.org\/10.1097\/ICB.0b013e3181578dd8","journal-title":"Retin Cases Brief Rep"},{"issue":"1","key":"3807_CR32","doi-asserted-by":"publisher","first-page":"12242","DOI":"10.1038\/s41598-017-12496-z","volume":"7","author":"M Subramani","year":"2017","unstructured":"Subramani M, Ponnalagu M, Krishna L, Jeyabalan N, Chevour P, Sharma A et al (2017) Resveratrol reverses the adverse effects of bevacizumab on cultured ARPE-19 cells. Sci Rep 7(1):12242. https:\/\/doi.org\/10.1038\/s41598-017-12496-z","journal-title":"Sci Rep"},{"issue":"12","key":"3807_CR33","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1080\/02713683.2017.1368085","volume":"42","author":"E Dinc","year":"2017","unstructured":"Dinc E, Ayaz L, Kurt AH (2017) Protective effect of combined caffeic acid phenethyl ester and bevacizumab against hydrogen peroxide-induced oxidative stress in human RPE cells. Curr Eye Res 42(12):1659\u20131666. https:\/\/doi.org\/10.1080\/02713683.2017.1368085","journal-title":"Curr Eye Res"},{"key":"3807_CR34","doi-asserted-by":"publisher","unstructured":"Motarjemizadeh G, Rajabzadeh M, Aidenloo NS, Valizadeh R (2017) Comparison of treatment response to intravitreal injection of triamcinolone, bevacizumab and combined form in patients with central retinal vein occlusion: a randomized clinical trial. Electron Physician 9(8):5068\u201375. https:\/\/doi.org\/10.19082\/5068","DOI":"10.19082\/5068"},{"issue":"11","key":"3807_CR35","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1007\/s10792-022-02333-2","volume":"42","author":"S Fekri","year":"2022","unstructured":"Fekri S, Soheilian M, Roozdar S, Abtahi SH, Nouri H (2022) The effect of vitamin D supplementation on the outcome of treatment with bevacizumab in diabetic macular edema: a randomized clinical trial. Int Ophthalmol 42(11):3345\u20133356. https:\/\/doi.org\/10.1007\/s10792-022-02333-2","journal-title":"Int Ophthalmol"},{"key":"3807_CR36","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1007\/s00417-021-05169-1","volume":"259","author":"H Nikkhah","year":"2021","unstructured":"Nikkhah H, Niazpour Moez R, Entezari M, Ramezani A, Hassanpour K, Karimi S et al (2021) Topical ketorolac as an adjunctive treatment with intravitreal bevacizumab in the management of diabetic macular edema: a double-masked placebo-controlled randomized clinical trial. Clin Exp Ophthalmol 259:2949\u20132959. https:\/\/doi.org\/10.1007\/s00417-021-05169-1","journal-title":"Clin Exp Ophthalmol"},{"key":"3807_CR37","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1007\/s00417-019-04383-2","volume":"257","author":"M Entezari","year":"2019","unstructured":"Entezari M, Flavarjani ZK, Ramezani A, Nikkhah H, Karimi S, Moghadam HF et al (2019) Combination of intravitreal bevacizumab and erythropoietin versus intravitreal bevacizumab alone for refractory diabetic macular edema: a randomized double-blind clinical trial. Clin Exp Ophthalmol 257:2375\u20132380. https:\/\/doi.org\/10.1007\/s00417-019-04383-2","journal-title":"Clin Exp Ophthalmol"},{"issue":"7","key":"3807_CR38","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1136\/bjophthalmol-2018-312244","volume":"103","author":"H Ahmadieh","year":"2019","unstructured":"Ahmadieh H, Nourinia R, Hafezi-Moghadam A, Sabbaghi H, Nakao S, Zandi S et al (2019) Intravitreal injection of a Rho-kinase inhibitor (fasudil) combined with bevacizumab versus bevacizumab monotherapy for diabetic macular oedema: a pilot randomised clinical trial. Br J Ophthalmol 103(7):922\u2013927. https:\/\/doi.org\/10.1136\/bjophthalmol-2018-312244","journal-title":"Br J Ophthalmol"},{"key":"3807_CR39","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s10792-016-0335-z","volume":"37","author":"H Ghanbari","year":"2017","unstructured":"Ghanbari H, Kianersi F, Sonbolestan SA, Abtahi MA, Akbari M, Abtahi ZA et al (2017) Intravitreal diclofenac plus bevacizumab versus bevacizumab alone in treatment-naive diabetic macular edema: a randomized double-blind clinical trial. Int Ophthalmol 37:867\u2013874. https:\/\/doi.org\/10.1007\/s10792-016-0335-z","journal-title":"Int Ophthalmol"},{"issue":"12","key":"3807_CR40","doi-asserted-by":"publisher","first-page":"6455","DOI":"10.3390\/ijms23126455","volume":"23","author":"WH Hu","year":"2022","unstructured":"Hu WH, Zhang XY, Leung KW, Duan R, Dong TX, Qin QW et al (2022) Resveratrol, an inhibitor binding to VEGF, restores the pathology of abnormal angiogenesis in retinopathy of prematurity (ROP) in mice: application by intravitreal and topical instillation. Int J Mol Sci 23(12):6455. https:\/\/doi.org\/10.3390\/ijms23126455","journal-title":"Int J Mol Sci"},{"issue":"2","key":"3807_CR41","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.tjo.2014.03.008","volume":"4","author":"M Nagpal","year":"2014","unstructured":"Nagpal M, Jain P, Rahud J, Mehrotra N (2014) Outcomes of combination therapy with dexamethasone implant and bevacizumab in macular edema related to vascular occlusions. Taiwan J Ophthalmol 4(2):77\u201381. https:\/\/doi.org\/10.1016\/j.tjo.2014.03.008","journal-title":"Taiwan J Ophthalmol"},{"issue":"1","key":"3807_CR42","doi-asserted-by":"publisher","first-page":"108","DOI":"10.18502\/jovr.v17i1.10175","volume":"17","author":"A Arabi","year":"2022","unstructured":"Arabi A, Tadayoni R, Ahmadieh H, Shahraki T, Nikkhah H (2022) Update on management of non-proliferative diabetic retinopathy without diabetic macular edema; is there a paradigm shift. J Ophthalmic Vis Res 17(1):108. https:\/\/doi.org\/10.18502\/jovr.v17i1.10175","journal-title":"J Ophthalmic Vis Res"},{"key":"3807_CR43","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1016\/j.jcjo.2017.09.026","volume":"52","author":"J Zhang","year":"2017","unstructured":"Zhang J, Upala S, Sanguankeo A (2017) Relationship between vitamin D deficiency and diabetic retinopathy: a meta-analysis. Can J Ophthalmol 52:S39-44. https:\/\/doi.org\/10.1016\/j.jcjo.2017.09.026","journal-title":"Can J Ophthalmol"},{"issue":"6","key":"3807_CR44","doi-asserted-by":"publisher","first-page":"3592","DOI":"10.1177\/11206721221076701","volume":"32","author":"SA Seyyar","year":"2022","unstructured":"Seyyar SA, Tokuc EO, T\u0131skao\u011flu NS, Karaba\u015f VL, G\u00fcng\u00f6r K (2022) Do serum vitamin D levels correlate with macular edema or with diabetic retinopathy. Eur J Ophthalmol 32(6):3592\u20133598. https:\/\/doi.org\/10.1177\/11206721221076701","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"3807_CR45","doi-asserted-by":"publisher","first-page":"34","DOI":"10.18502\/jovr.v16i1.8249","volume":"16","author":"S Karimi","year":"2021","unstructured":"Karimi S, Movafaghi V, Arabi A, Shahraki T, Safi S (2021) Effects of oral vitamin D supplement therapy on clinical outcomes of intravitreal bevacizumab in diabetic macular edema. J Ophthalmic Vis Res 16(1):34. https:\/\/doi.org\/10.18502\/jovr.v16i1.8249","journal-title":"J Ophthalmic Vis Res"},{"issue":"3","key":"3807_CR46","doi-asserted-by":"publisher","first-page":"376","DOI":"10.18502\/jovr.v17i3.11575","volume":"17","author":"S Karimi","year":"2022","unstructured":"Karimi S, Parvizi F, Arabi A, Shahraki T, Safi S (2022) Oral vitamin D supplementation and clinical outcomes of intravitreal bevacizumab injection for macular edema secondary to retinal vein occlusions. J Ophthalmic Vis Res 17(3):376. https:\/\/doi.org\/10.18502\/jovr.v17i3.11575","journal-title":"J Ophthalmic Vis Res"},{"key":"3807_CR47","doi-asserted-by":"publisher","DOI":"10.54905\/disssi\/v27i135\/e237ms2731","volume":"27","author":"V Kandambeth","year":"2023","unstructured":"Kandambeth V, Mathurkar S, Daigavane S (2023) A rare case of bilateral central retinal vein occlusion in a patient with vitamin D deficiency. Med Sci 27:e237ms2731. https:\/\/doi.org\/10.54905\/disssi\/v27i135\/e237ms2731","journal-title":"Med Sci"},{"issue":"7","key":"3807_CR48","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.3390\/pharmaceutics13071102","volume":"13","author":"A Arrigo","year":"2021","unstructured":"Arrigo A, Bandello F (2021) Molecular features of classic retinal drugs, retinal therapeutic targets and emerging treatments. Pharmaceutics 13(7):1102. https:\/\/doi.org\/10.3390\/pharmaceutics13071102","journal-title":"Pharmaceutics"},{"issue":"7","key":"3807_CR49","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.3390\/antiox12071379","volume":"12","author":"N Kushwah","year":"2023","unstructured":"Kushwah N, Bora K, Maurya M, Pavlovich MC, Chen J (2023) Oxidative stress and anti-oxidants in age-related macular degeneration. Antioxidants 12(7):1379. https:\/\/doi.org\/10.3390\/antiox12071379","journal-title":"Antioxidants"},{"key":"3807_CR50","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/3420187","volume":"2018","author":"MY Wu","year":"2018","unstructured":"Wu MY, Yiang GT, Lai TT, Li CJ (2018) The oxidative stress and mitochondrial dysfunction during the pathogenesis of diabetic retinopathy. Oxid Med Cell Longev 2018:3420187. https:\/\/doi.org\/10.1155\/2018\/3420187","journal-title":"Oxid Med Cell Longev"},{"issue":"4","key":"3807_CR51","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2174\/1574885514666191007101007","volume":"15","author":"DS Sharma","year":"2020","unstructured":"Sharma DS, Singh SK, Thakur D, Kr A, Khursheed R, Wadhwa S (2020) Current strategies and future perspective for the effective treatment of diabetic retinopathy. Curr Drug Ther 15(4):299\u2013311. https:\/\/doi.org\/10.2174\/1574885514666191007101007","journal-title":"Curr Drug Ther"},{"issue":"4","key":"3807_CR52","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.mam.2012.03.009","volume":"33","author":"SG Jarrett","year":"2012","unstructured":"Jarrett SG, Boulton ME (2012) Consequences of oxidative stress in age-related macular degeneration. Mol Aspects Med 33(4):399\u2013417. https:\/\/doi.org\/10.1016\/j.mam.2012.03.009","journal-title":"Mol Aspects Med"},{"key":"3807_CR53","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s10522-013-9463-2","volume":"14","author":"P Tokarz","year":"2013","unstructured":"Tokarz P, Kaarniranta K, Blasiak J (2013) Role of anti-oxidant enzymes and small molecular weight anti-oxidants in the pathogenesis of age-related macular degeneration (AMD). Biogerontology 14:461\u2013482. https:\/\/doi.org\/10.1007\/s10522-013-9463-2","journal-title":"Biogerontology"},{"issue":"1","key":"3807_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40942-016-0044-9","volume":"2","author":"VC Lima","year":"2016","unstructured":"Lima VC, Rosen RB, Farah M (2016) Macular pigment in retinal health and disease. Int J Retina Vitreous 2(1):1\u20139. https:\/\/doi.org\/10.1186\/s40942-016-0044-9","journal-title":"Int J Retina Vitreous"},{"issue":"2","key":"3807_CR55","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.3390\/ijms15021865","volume":"15","author":"AJ Payne","year":"2014","unstructured":"Payne AJ, Kaja S, Naumchuk Y, Kunjukunju N, Koulen P (2014) Anti-oxidant drug therapy approaches for neuroprotection in chronic diseases of the retina. Int J Mol Sci 15(2):1865\u20131886. https:\/\/doi.org\/10.3390\/ijms15021865","journal-title":"Int J Mol Sci"},{"issue":"40","key":"3807_CR56","doi-asserted-by":"publisher","first-page":"4742","DOI":"10.2174\/1381612825666190115122622","volume":"24","author":"R Lenin","year":"2018","unstructured":"Lenin R, Thomas SM, Gangaraju R (2018) Endothelial activation and oxidative stress in neurovascular defects of the retina. Curr Pharm Des 24(40):4742\u20134754. https:\/\/doi.org\/10.2174\/1381612825666190115122622","journal-title":"Curr Pharm Des"},{"issue":"15","key":"3807_CR57","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.2174\/092986706777452515","volume":"13","author":"A Soro-Paavonen","year":"2006","unstructured":"Soro-Paavonen A, Forbes J (2006) Novel therapeutics for diabetic micro-and macrovascular complications. Curr Med Chem 13(15):1777\u20131788. https:\/\/doi.org\/10.2174\/092986706777452515","journal-title":"Curr Med Chem"},{"key":"3807_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13340-013-0148-5","volume":"5","author":"S Hagiwara","year":"2014","unstructured":"Hagiwara S, Jha JC, Cooper ME (2014) Identifying and interpreting novel targets that address more than one diabetic complication: a strategy for optimal end organ protection in diabetes. Diabetol Int 5:1\u201320. https:\/\/doi.org\/10.1007\/s13340-013-0148-5","journal-title":"Diabetol Int"},{"issue":"8","key":"3807_CR59","doi-asserted-by":"publisher","first-page":"810","DOI":"10.2174\/138920110793262079","volume":"11","author":"B Juhasz","year":"2010","unstructured":"Juhasz B, Varga B, Gesztelyi R, Kemeny-Beke A, Zsuga J, Tosaki A (2010) Resveratrol: a multifunctional cytoprotective molecule. Curr Pharm Biotechnol 11(8):810\u2013818. https:\/\/doi.org\/10.2174\/138920110793262079","journal-title":"Curr Pharm Biotechnol"},{"issue":"4","key":"3807_CR60","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1021\/acs.jafc.8b05977","volume":"67","author":"WH Hu","year":"2018","unstructured":"Hu WH, Duan R, Xia YT, Xiong QP, Wang HY, Chan GKL et al (2018) Binding of resveratrol to vascular endothelial growth factor suppresses angiogenesis by inhibiting the receptor signaling. J Agric Food Chem 67(4):1127\u20131137. https:\/\/doi.org\/10.1021\/acs.jafc.8b05977","journal-title":"J Agric Food Chem"},{"issue":"5","key":"3807_CR61","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3390\/molecules26051335","volume":"26","author":"B Olgierd","year":"2021","unstructured":"Olgierd B, Kamila \u017b, Anna B, Emilia M (2021) The pluripotent activities of caffeic acid phenethyl ester. Molecules 26(5):1335. https:\/\/doi.org\/10.3390\/molecules26051335","journal-title":"Molecules"},{"key":"3807_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113297","volume":"153","author":"S Bastani","year":"2022","unstructured":"Bastani S, Vahedian V, Rashidi M, Mir A, Mirzaei S, Alipourfard I et al (2022) An evaluation on potential anti-oxidant and anti-inflammatory effects of Crocin. Biomed Pharmacother 153:113297. https:\/\/doi.org\/10.1016\/j.biopha.2022.113297","journal-title":"Biomed Pharmacother"},{"key":"3807_CR63","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ajo.2018.03.007","volume":"190","author":"S Sepahi","year":"2018","unstructured":"Sepahi S, Mohajeri SA, Hosseini SM, Khodaverdi E, Shoeibi N, Namdari M et al (2018) Effects of crocin on diabetic maculopathy: a placebo-controlled randomized clinical trial. Am J Ophthalmol 190:89\u201398. https:\/\/doi.org\/10.1016\/j.ajo.2018.03.007","journal-title":"Am J Ophthalmol"},{"key":"3807_CR64","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.ejpb.2015.02.027","volume":"95","author":"R Hennig","year":"2015","unstructured":"Hennig R, Goepferich A (2015) Nanoparticles for the treatment of ocular neovascularizations. Eur J Pharm Biopharm 95:294\u2013306. https:\/\/doi.org\/10.1016\/j.ejpb.2015.02.027","journal-title":"Eur J Pharm Biopharm"},{"key":"3807_CR65","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.tifs.2018.07.009","volume":"79","author":"S Khorasani","year":"2018","unstructured":"Khorasani S, Danaei M, Mozafari MR (2018) Nanoliposome technology for the food and nutraceutical industries. Trends Food Sci Technol 79:106\u2013115. https:\/\/doi.org\/10.1016\/j.tifs.2018.07.009","journal-title":"Trends Food Sci Technol"},{"key":"3807_CR66","doi-asserted-by":"publisher","unstructured":"Montoya-\u00c1lvarez M, Gonzalez-Perez J, Londo\u00f1o ME (2022) Diabetic retinopathy treatments based on nanotechnology. Sci Open Preprints. https:\/\/doi.org\/10.14293\/S2199-1006.1.SOR-.PPQOQ83.v2","DOI":"10.14293\/S2199-1006.1.SOR-.PPQOQ83.v2"},{"key":"3807_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119895","volume":"590","author":"M Malakouti-Nejad","year":"2020","unstructured":"Malakouti-Nejad M, Bardania H, Aliakbari F, Baradaran-Rafii A, Elahi E, Monti D et al (2020) Formulation of nanoliposome-encapsulated bevacizumab (Avastin): statistical optimization for enhanced drug encapsulation and properties evaluation. Int J Pharm 590:119895. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.119895","journal-title":"Int J Pharm"},{"key":"3807_CR68","doi-asserted-by":"publisher","unstructured":"Vinkovi\u0107 M, Bosnar D, Tedeschi Reiner E, De Salvo G, Mati\u0107 S (2020) Combined treatment with bevacizumab and triamcinolone acetonide for macular edema due to retinal vein occlusion. Acta Clin Croat 59(4):569\u201375. https:\/\/doi.org\/10.20471\/acc.2020.59.04.01","DOI":"10.20471\/acc.2020.59.04.01"},{"issue":"4","key":"3807_CR69","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00592-021-01824-5","volume":"59","author":"TC Lin","year":"2022","unstructured":"Lin TC, Chung YC, Hsu TK, Huang HW, Huang YM, Chou YC et al (2022) Therapeutic effect of simultaneous intravitreal dexamethasone and aflibercept on diabetic macular edema. Acta Diabetol 59(4):501\u2013508. https:\/\/doi.org\/10.1007\/s00592-021-01824-5","journal-title":"Acta Diabetol"},{"issue":"4","key":"3807_CR70","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1159\/000499540","volume":"62","author":"D Zur","year":"2019","unstructured":"Zur D, Igliki M, Loewenstein A (2019) The role of steroids in the management of diabetic macular edema. Ophthalmic Res 62(4):231\u2013236. https:\/\/doi.org\/10.1159\/000499540","journal-title":"Ophthalmic Res"},{"issue":"2","key":"3807_CR71","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/IAE.0b013e3180323de7","volume":"27","author":"AJ Augustin","year":"2007","unstructured":"Augustin AJ, Puls S, Offermann I (2007) Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 27(2):133\u2013140. https:\/\/doi.org\/10.1097\/IAE.0b013e3180323de7","journal-title":"Retina"},{"issue":"8","key":"3807_CR72","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/j.drudis.2019.03.022","volume":"24","author":"A Arranz-Romera","year":"2019","unstructured":"Arranz-Romera A, Esteban-Perez S, Garcia-Herranz D, Aragon-Navas A, Bravo-Osuna I, Herrero-Vanrell R (2019) Combination therapy and co-delivery strategies to optimize treatment of posterior segment neuro-degenerative diseases. Drug Discov Today 24(8):1644\u20131653. https:\/\/doi.org\/10.1016\/j.drudis.2019.03.022","journal-title":"Drug Discov Today"},{"issue":"1","key":"3807_CR73","first-page":"4","volume":"5","author":"FL De Andrade","year":"2016","unstructured":"De Andrade FL, Lopes FS, de Andrade GC, Prata TS, Andre M (2016) Simultaneous therapy with intravitreal dexamethasone implant and bevacizumab for the treatment of macular edema. Med Hypothesis Discov Innov Ophthalmol 5(1):4","journal-title":"Med Hypothesis Discov Innov Ophthalmol"},{"key":"3807_CR74","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2024.2413692","author":"P Wu","year":"2024","unstructured":"Wu P, Xing X, Huan Y, Li X, Yang Y, Zhang J et al (2024) Intravitreal dexamethasone implants for macular edema secondary to acute retinal necrosis. Ocul Immunol Inflamm. https:\/\/doi.org\/10.1080\/09273948.2024.2413692","journal-title":"Ocul Immunol Inflamm"},{"key":"3807_CR75","doi-asserted-by":"publisher","unstructured":"Tang HX, Yang YQ, Yuan Y, Li JJ, Mei Z, Zou H (2021) Ozurdex treatment for retinal conditions: a systematic review and meta-analysis. Res Square. https:\/\/doi.org\/10.21203\/rs.3.rs-1049836\/v1","DOI":"10.21203\/rs.3.rs-1049836\/v1"},{"issue":"10","key":"3807_CR76","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1136\/bjophthalmol-2016-309882","volume":"101","author":"SS Wickremasinghe","year":"2017","unstructured":"Wickremasinghe SS, Fraser-Bell S, Alessandrello E, Mehta H, Gillies MC, Lim LL (2017) Retinal vascular calibre changes after intravitreal bevacizumab or dexamethasone implant treatment for diabetic macular oedema. Br J Ophthalmol 101(10):1329\u20131333. https:\/\/doi.org\/10.1136\/bjophthalmol-2016-309882","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"3807_CR77","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1136\/bjophthalmol-2015-307797","volume":"100","author":"H Mehta","year":"2016","unstructured":"Mehta H, Fraser-Bell S, Yeung A, Campain A, Lim LL, Quin GJ et al (2016) Efficacy of dexamethasone versus bevacizumab on regression of hard exudates in diabetic maculopathy: data from the bevordex randomised clinical trial. Br J Ophthalmol 100(7):1000\u20131004. https:\/\/doi.org\/10.1136\/bjophthalmol-2015-307797","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"3807_CR78","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.5301\/ejo.5000715","volume":"26","author":"A Stepanov","year":"2016","unstructured":"Stepanov A, Codenotti M, Ramoni A, Prati M, Jiraskova N, Rozsival P et al (2016) Anterior chamber migration of dexamethasone intravitreal implant (Ozurdex\u00ae) through basal iridectomy (Ando) in a pseudophakic patient. Eur J Ophthalmol 26(3):e52\u2013e54. https:\/\/doi.org\/10.5301\/ejo.5000715","journal-title":"Eur J Ophthalmol"},{"issue":"7","key":"3807_CR79","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/eye.2013.79","volume":"27","author":"W Mayer","year":"2013","unstructured":"Mayer W, Wolf A, Kernt M, Kook D, Kampik A, Ulbig M et al (2013) Twelve-month experience with Ozurdex for the treatment of macular edema associated with retinal vein occlusion. Eye 27(7):816\u2013822. https:\/\/doi.org\/10.1038\/eye.2013.79","journal-title":"Eye"},{"issue":"7","key":"3807_CR80","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1097\/IAE.0b013e318242b838","volume":"32","author":"MA Singer","year":"2012","unstructured":"Singer MA, Bell DJ, Woods P, Pollard J, Boord T, Herro A et al (2012) Effect of combination therapy with bevacizumab and dexamethasone intravitreal implant in patients with retinal vein occlusion. Retina 32(7):1289\u20131294. https:\/\/doi.org\/10.1097\/IAE.0b013e318242b838","journal-title":"Retina"},{"issue":"1","key":"3807_CR81","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3341\/kjo.2016.0134","volume":"32","author":"SY Moon","year":"2018","unstructured":"Moon SY, Cho KH, Woo SJ, Park SP, Kim YK (2018) Bevacizumab versus dexamethasone implant followed by bevacizumab for the treatment of macula edema associated with branch retinal vein occlusion. Korean J Ophthalmol 32(1):29. https:\/\/doi.org\/10.3341\/kjo.2016.0134","journal-title":"Korean J Ophthalmol"},{"issue":"8","key":"3807_CR82","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1097\/IAE.0000000000000533","volume":"35","author":"RK Maturi","year":"2015","unstructured":"Maturi RK, Bleau L, Saunders J, Mubasher M, Stewart MW (2015) A 12-month, single-masked, randomized controlled study of eyes with persistent diabetic macular edema after multiple anti-VEGF injections to assess the efficacy of the dexamethasone-delayed delivery system as an adjunct to bevacizumab compared with continued bevacizumab monotherapy. Retina 35(8):1604\u20131614. https:\/\/doi.org\/10.1097\/IAE.0000000000000533","journal-title":"Retina"},{"issue":"2","key":"3807_CR83","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3109\/15569527.2015.1127254","volume":"36","author":"E G\u00fcler","year":"2017","unstructured":"G\u00fcler E, Totan Y, Bet\u00fcl G\u00fcraga\u00e7 F (2017) Intravitreal bevacizumab and dexamethasone implant for treatment of chronic diabetic macular edema. Cutaneous Ocul Toxicol 36(2):180\u2013184","journal-title":"Cutaneous Ocul Toxicol"},{"issue":"7","key":"3807_CR84","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11071901","volume":"11","author":"LA Aceves-Franco","year":"2023","unstructured":"Aceves-Franco LA, Sanchez-Aguilar OE, Barragan-Arias AR, Ponce-Gallegos MA, Navarro-Partida J, Santos A (2023) The evolution of triamcinolone acetonide therapeutic use in retinal diseases: from off-label intravitreal injection to advanced nano-drug delivery systems. Biomedicines 11(7):1901. https:\/\/doi.org\/10.3390\/biomedicines11071901","journal-title":"Biomedicines"},{"key":"3807_CR85","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s40265-017-0704-6","volume":"77","author":"SU Shah","year":"2017","unstructured":"Shah SU, Maturi RK (2017) Therapeutic options in refractory diabetic macular oedema. Drugs 77:481\u2013492. https:\/\/doi.org\/10.1007\/s40265-017-0704-6","journal-title":"Drugs"},{"issue":"4","key":"3807_CR86","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1097\/IAE.0b013e31823043c6","volume":"32","author":"CK Chan","year":"2012","unstructured":"Chan CK, Lai TY, Mohamed S, Lee VY, Liu DT, Li CL et al (2012) Combined high-dose sub-tenon triamcinolone, intravitreal bevacizumab, and laser photocoagulation for refractory diabetic macular edema: a pilot study. Retina 32(4):672\u2013678. https:\/\/doi.org\/10.1097\/IAE.0b013e31823043c6","journal-title":"Retina"},{"issue":"6","key":"3807_CR87","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.ophtha.2009.01.011","volume":"116","author":"M Soheilian","year":"2009","unstructured":"Soheilian M, Ramezani A, Obudi A, Bijanzadeh B, Salehipour M, Yaseri M et al (2009) Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 116(6):1142\u20131150. https:\/\/doi.org\/10.1016\/j.ophtha.2009.01.011","journal-title":"Ophthalmology"},{"issue":"1","key":"3807_CR88","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12886-023-02790-y","volume":"23","author":"F Fazel","year":"2023","unstructured":"Fazel F, Malekahmadi M, Feizi A, Oliya B, Tavakoli M, Fazel M (2023) Suprachoroidal injection of triamcinolone acetonide plus intravitreal bevacizumab in diabetic macular edema: a randomized pilot trial. BMC Ophthalmol 23(1):40. https:\/\/doi.org\/10.1186\/s12886-023-02790-y","journal-title":"BMC Ophthalmol"},{"issue":"2","key":"3807_CR89","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1001\/jamaophthalmol.2013.5692","volume":"132","author":"SD Schoenberger","year":"2014","unstructured":"Schoenberger SD, Kim SJ, Sheng J, Calcutt MW (2014) Reduction of vitreous prostaglandin E2 levels after topical administration of ketorolac 0.45%. JAMA Ophthalmol 132(2):150\u2013154. https:\/\/doi.org\/10.1001\/jamaophthalmol.2013.5692","journal-title":"JAMA Ophthalmol"},{"key":"3807_CR90","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00417-017-3816-5","volume":"256","author":"MB Kashkouli","year":"2018","unstructured":"Kashkouli MB, Yousefi S, Nojomi M, Sanjari MS, Pakdel F, Entezari M et al (2018) Traumatic optic neuropathy treatment trial (TONTT): open label, phase 3, multicenter, semi-experimental trial. Clin Exp Ophthalmol 256:209\u2013218. https:\/\/doi.org\/10.1007\/s00417-017-3816-5","journal-title":"Clin Exp Ophthalmol"},{"key":"3807_CR91","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1007\/s00417-014-2691-6","volume":"252","author":"M Entezari","year":"2014","unstructured":"Entezari M, Esmaeili M, Yaseri M (2014) A pilot study of the effect of intravenous erythropoetin on improvement of visual function in patients with recent indirect traumatic optic neuropathy. Clin Exp Ophthalmol 252:1309\u20131313. https:\/\/doi.org\/10.1007\/s00417-014-2691-6","journal-title":"Clin Exp Ophthalmol"},{"issue":"2","key":"3807_CR92","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1167\/iovs.07-0721","volume":"49","author":"J Zhang","year":"2008","unstructured":"Zhang J, Wu Y, Jin Y, Ji F, Sinclair SH, Luo Y et al (2008) Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes. Invest Ophthalmol Vis Sci 49(2):732\u2013742. https:\/\/doi.org\/10.1167\/iovs.07-0721","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"3807_CR93","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3928\/15428877-20091230-03","volume":"41","author":"W Li","year":"2010","unstructured":"Li W, Sinclair SH, Xu GT (2010) Effects of intravitreal erythropoietin therapy for patients with chronic and progressive diabetic macular edema. Ophthalmic Surg Lasers Imaging Retina 41(1):18\u201325. https:\/\/doi.org\/10.3928\/15428877-20091230-03","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"1","key":"3807_CR94","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2337\/db08-0762","volume":"58","author":"R Arita","year":"2009","unstructured":"Arita R, Hata Y, Nakao S, Kita T, Miura M, Kawahara S et al (2009) Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage. Diabetes 58(1):215\u2013226. https:\/\/doi.org\/10.2337\/db08-0762","journal-title":"Diabetes"},{"issue":"1","key":"3807_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bjophthalmol-2017-310378","volume":"102","author":"R Nourinia","year":"2018","unstructured":"Nourinia R, Nakao S, Zandi S, Safi S, Hafezi-Moghadam A, Ahmadieh H (2018) Rock inhibitors for the treatment of ocular diseases. Br J Ophthalmol 102(1):1\u20135. https:\/\/doi.org\/10.1136\/bjophthalmol-2017-310378","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"3807_CR96","first-page":"337","volume":"8","author":"R Nourinia","year":"2013","unstructured":"Nourinia R, Ahmadieh H, Shahheidari MH, Zandi S, Nakao S, Hafezi-Moghadam A (2013) Intravitreal fasudil combined with bevacizumab for treatment of refractory diabetic macular edema; a pilot study. J Ophthalmic Vis Res 8(4):337","journal-title":"J Ophthalmic Vis Res"},{"issue":"3","key":"3807_CR97","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/jop.2006.134","volume":"23","author":"M Shimura","year":"2007","unstructured":"Shimura M, Nakazawa T, Yasuda K, Nishida K (2007) Diclofenac prevents an early event of macular thickening after cataract surgery in patients with diabetes. J Ocul Pharmacol Ther 23(3):284\u2013291. https:\/\/doi.org\/10.1089\/jop.2006.134","journal-title":"J Ocul Pharmacol Ther"},{"issue":"4","key":"3807_CR98","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/01.ijg.0000169389.09804.33","volume":"14","author":"JD Henderer","year":"2005","unstructured":"Henderer JD, Wilson RP, Moster MR, Myers J, Schmidt C, Fontanarosa J et al (2005) Timolol\/dorzolamide combination therapy as initial treatment for intraocular pressure over 30 mm hg. J Glaucoma 14(4):267\u2013270. https:\/\/doi.org\/10.1097\/01.ijg.0000169389.09804.33","journal-title":"J Glaucoma"},{"issue":"1","key":"3807_CR99","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10792-024-03005-z","volume":"44","author":"S Fekri","year":"2024","unstructured":"Fekri S, Rabiei A, Hooshmandi S, Nouri H, Abtahi SH (2024) The effect of combination therapy with intravitreal bevacizumab and topical timolol\u2013dorzolamide eye drops on diabetic macular edema: a double-blind randomized controlled trial. Int Ophthalmol 44(1):101. https:\/\/doi.org\/10.1007\/s10792-024-03005-z","journal-title":"Int Ophthalmol"},{"issue":"5","key":"3807_CR100","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1111\/bcp.13871","volume":"85","author":"F Semeraro","year":"2019","unstructured":"Semeraro F, Gambicordi E, Cancarini A, Morescalchi F, Costagliola C, Russo A (2019) Treatment of exudative age-related macular degeneration with aflibercept combined with pranoprofen eye drops or nutraceutical support with omega-3: a randomized trial. Br J Clin Pharmacol 85(5):908\u2013913. https:\/\/doi.org\/10.1111\/bcp.13871","journal-title":"Br J Clin Pharmacol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03807-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-025-03807-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03807-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T19:01:51Z","timestamp":1766170911000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-025-03807-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":100,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3807"],"URL":"https:\/\/doi.org\/10.1007\/s10792-025-03807-9","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"assertion":[{"value":"3 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"437"}}